331 related articles for article (PubMed ID: 22123689)
1. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
Moss JA; Srinivasan P; Smith TJ; Butkyavichene I; Lopez G; Brooks AA; Martin A; Dinh CT; Smith JM; Baum MM
Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
[TBL] [Abstract][Full Text] [Related]
3. An intravaginal ring for the simultaneous delivery of multiple drugs.
Baum MM; Butkyavichene I; Gilman J; Kennedy S; Kopin E; Malone AM; Nguyen C; Smith TJ; Friend DR; Clark MR; Moss JA
J Pharm Sci; 2012 Aug; 101(8):2833-43. PubMed ID: 22619076
[TBL] [Abstract][Full Text] [Related]
4. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
Johnson TJ; Clark MR; Albright TH; Nebeker JS; Tuitupou AL; Clark JT; Fabian J; McCabe RT; Chandra N; Doncel GF; Friend DR; Kiser PF
Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.
Moss JA; Malone AM; Smith TJ; Butkyavichene I; Cortez C; Gilman J; Kennedy S; Kopin E; Nguyen C; Sinha P; Hendry RM; Guenthner P; Holder A; Martin A; McNicholl J; Mitchell J; Pau CP; Srinivasan P; Smith JM; Baum MM
Antimicrob Agents Chemother; 2012 Nov; 56(11):5952-60. PubMed ID: 22964245
[TBL] [Abstract][Full Text] [Related]
6. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.
Smith JM; Moss JA; Srinivasan P; Butkyavichene I; Gunawardana M; Fanter R; Miller CS; Sanchez D; Yang F; Ellis S; Zhang J; Marzinke MA; Hendrix CW; Kapoor A; Baum MM
PLoS One; 2017; 12(10):e0185946. PubMed ID: 28982161
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
Shankar GN; Alt C
J Antimicrob Chemother; 2014 Dec; 69(12):3282-93. PubMed ID: 25139839
[TBL] [Abstract][Full Text] [Related]
9. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Moss JA; Butkyavichene I; Churchman SA; Gunawardana M; Fanter R; Miller CS; Yang F; Easley JT; Marzinke MA; Hendrix CW; Smith TJ; Baum MM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321
[TBL] [Abstract][Full Text] [Related]
10. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.
Friend DR
Expert Opin Drug Deliv; 2012 Apr; 9(4):417-27. PubMed ID: 22385316
[TBL] [Abstract][Full Text] [Related]
12. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
Nixon B; Jandl T; Teller RS; Taneva E; Wang Y; Nagaraja U; Kiser PF; Herold BC
Antimicrob Agents Chemother; 2014; 58(2):1153-60. PubMed ID: 24323471
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.
Herold BC; Dezzutti CS; Richardson BA; Marrazzo J; Mesquita PM; Carpenter C; Huber A; Louissaint N; Marzinke MA; Hillier SL; Hendrix CW
J Acquir Immune Defic Syndr; 2014 May; 66(1):65-73. PubMed ID: 24457633
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
Clark MR; Friend DR
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of microporous polycaprolactone matrices for controlled delivery of antiviral microbicides to the female genital tract.
Asvadi NH; Dang NT; Davis-Poynter N; Coombes AG
J Mater Sci Mater Med; 2013 Dec; 24(12):2719-27. PubMed ID: 23892484
[TBL] [Abstract][Full Text] [Related]
17. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.
Smith JM; Rastogi R; Teller RS; Srinivasan P; Mesquita PM; Nagaraja U; McNicholl JM; Hendry RM; Dinh CT; Martin A; Herold BC; Kiser PF
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16145-50. PubMed ID: 24043812
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
19. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
